Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine

Andrea Kuendgen, MD, Catharina Müller-Thomas, MD, Petra Urbaniak, Michael Lauseker, Torsten Haferlach, MD, Tamara Alpermann, Andreia Albuquerque, PhD, Alexander Kohlmann, PhD, Susanne Schnittger, PhD, Barbara Hildebrandt, PhD, Brigitte Royer-Pokora, PhD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, MD, Katharina Götze, MD

Blood (2013) 122 (21): 2757.

https://doi.org/10.1182/blood.V122.21.2757.2757

Published: 2013

Journal Articles

Prognostic Impact Of Molecular Mutations In 182 Patients With Myelodysplastic Syndromes

Andrea Kuendgen, MD, Jenny Seidler, Michael Lauseker, Torsten Haferlach, MD, Susanne Schnittger, PhD, Alexander Kohlmann, PhD, Barbara Hildebrandt, PhD, Catharina Müller-Thomas, MD, Beate Betz, PhD, Rainer Haas, MD, Norbert Gattermann, MD, Brigitte Royer-Pokora, PhD, Katharina Götze, M.D., Ulrich Germing, MD

Blood (2013) 122 (21): 2758.

https://doi.org/10.1182/blood.V122.21.2758.2758

Published: 2013

Journal Articles

An Analysis of Treatment Choices for Acute Myeloid Leukemia in Patients 60 Years and Older from the University of Duesseldorf AML/MDS Database.

Viola Klaerner, MD, Andrea Kuendgen, MD, Peter De Porre, PhD, Barbara Hildebrandt, PhD, Rainer Haas, MD, Norbert Gattermann, MD, Ulrich Germing, MD

Blood (2007) 110 (11): 4378.

https://doi.org/10.1182/blood.V110.11.4378.4378

Published: 2007

Journal Articles

Prognostic Factors in Treatment-Related Myelodysplastic Syndromes (t-MDS) and Acute Myeloid Leukemia (t-AML).

Andrea Kuendgen, MD, Claudia Mende, MD, Detlef Haase, MD, Stephanie Fischer, MD, Barbara Hildebrandt, PhD, Aristoteles Giagounidis, MD, Rainer Haas, MD, Norbert Gattermann, MD, Ulrich Germing, MD

Blood (2007) 110 (11): 2451.

https://doi.org/10.1182/blood.V110.11.2451.2451

Published: 2007

Journal Articles

Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.

Detlef Haase, MD, PhD, Ulrich Germing, MD, PhD, Julie Schanz, MD, Michael Pfeilstoecker, MD, PhD, Barbara Hildebrandt, PhD, Michael Luebbert, MD, PhD, Aristoteles Giagounidis, MD, Carlo Aul, MD, PhD, Lorenz Truemper, MD, PhD, Thomas Mueller, PhD, Peter Valent, MD, PhD, Norbert Gattermann, MD, PhD, Christa Fonatsch, PhD, Otto Krieger, MD, PhD, Reinhard Stauder, MD, Christian Steidl, MD

Blood (2006) 108 (11): 252.

https://doi.org/10.1182/blood.V108.11.252.252

Published: 2006

Journal Articles

New and Comprehensive Cytogenetic Prognostication and Categorization in MDS.

Detlef Haase, MD, PhD, Ulrich Germing, MD, PhD, Julie Schanz, MD, Michael Pfeilstoecker, MD, PhD, Thomas Noesslinger, MD, Barbara Hildebrandt, PhD, Andrea Kuendgen, MD, Michael Luebbert, MD, PhD, Aristoteles Giagounidis, MD, Carlo Aul, MD, PhD, Lorenz Truemper, MD, PhD, Thomas Mueller, PhD, Peter Valent, MD PhD, Christa Fonatsch, MD, PhD, Christian Steidl, MD

Blood (2006) 108 (11): 248.

https://doi.org/10.1182/blood.V108.11.248.248

Published: 2006

Journal Articles

Sequential Cytogenetic Analyses of 577 Patients with Myelodysplastic Syndromes: Correlations between Initial Karyotype, Cytogenetic Dynamics, and Clinical Course.

Christian Steidl, MD, Rainer Schabla, MD, Ulrich Germing, MD, PhD, Barbara Hildebrandt, PhD, Thomas Noesslinger, MD, Michael Pfeilstoecker, MD, PhD, Aristoteles Giagounidis, MD, PhD, Regina Kunzmann, PhD, Peter Haas, MD, Michael Luebbert, MD, PhD, Lorenz Truemper, MD, PhD, Detlef Haase, MD, PhD

Blood (2005) 106 (11): 2531.

https://doi.org/10.1182/blood.V106.11.2531.2531

Published: 2005

Journal Articles

A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.

Luca Malcovati, MD, Ulrich Germing, MD, Andrea Kuendgen, MD, Matteo G. Della Porta, MD, Rosangela Invernizzi, MD, Aristoteles Giagounidis, MD, Barbara Hildebrandt, PhD, Paolo Bernasconi, MD, Sabine Knipp, MD, Mario Lazzarino, MD, Corinna Strupp, MD, Mario Cazzola, MD

Blood (2005) 106 (11): 788.

https://doi.org/10.1182/blood.V106.11.788.788

Published: 2005

Journal Articles

Intensive Chemotherapy Is Not Recommended for Patients with AML or High-Risk MDS Aged over 60 Years with Complex Karyotype Anomalies.

Sabine Knipp, MD, Barbara Hildebrandt, PhD, Aristoteles A.N. Giagounidis, MD, Guido Kobbe, MD, Rainer Haas, MD, Carlo Aul, MD, Norbert Gattermann, MD, Ulrich Germing, MD

Blood (2004) 104 (11): 72.

https://doi.org/10.1182/blood.V104.11.72.72

Published: 2004

Journal Articles

Phase 2 Trial of the Histone Deacetylase Inhibitor Valproic Acid as a Monotherapy or in Combination with All-Trans Retinoic Acid in 24 Patients with Acute Myeloid Leukemia.

Andrea Kuendgen, MD, Corinna Strupp, MD, Barbara Hildebrandt, PhD, Sabine Knipp, MD, Baerbel Junge, Rainer Haas, MD, Ulrich Germing, MD, Norbert Gattermann, MD

Blood (2004) 104 (11): 1808.

https://doi.org/10.1182/blood.V104.11.1808.1808

Published: 2004

NARROW

Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine

Prognostic Impact Of Molecular Mutations In 182 Patients With Myelodysplastic Syndromes

An Analysis of Treatment Choices for Acute Myeloid Leukemia in Patients 60 Years and Older from the University of Duesseldorf AML/MDS Database.

Prognostic Factors in Treatment-Related Myelodysplastic Syndromes (t-MDS) and Acute Myeloid Leukemia (t-AML).

Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.

New and Comprehensive Cytogenetic Prognostication and Categorization in MDS.

Sequential Cytogenetic Analyses of 577 Patients with Myelodysplastic Syndromes: Correlations between Initial Karyotype, Cytogenetic Dynamics, and Clinical Course.

A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.

Intensive Chemotherapy Is Not Recommended for Patients with AML or High-Risk MDS Aged over 60 Years with Complex Karyotype Anomalies.

Phase 2 Trial of the Histone Deacetylase Inhibitor Valproic Acid as a Monotherapy or in Combination with All-Trans Retinoic Acid in 24 Patients with Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only